Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MIRAthis companyMIRA Pharmaceuticals, Inc.	$0.59	-1.12×	3.44×	0×	-2.82×	-51.0%	0.0%	0.0%	0.0%	-100.5%	-101.0%	-13.0%	0×	0.61×	0×	15.75×	0.0%	2	320.98	1	C-
ANTXAN2 Therapeutics, Inc.	$4.00	-0.98×	0.65×	0×	-0.41×	-86.4%	0.0%	0.0%	0.0%	-66.3%	-71.6%	-86.6%	0×	0.57×	0×	6.87×	0.0%	1	12.25	1	C-
APUSApimeds Pharmaceuticals US, Inc	$2.69	-2.98×	0.12×	0×	-4.2×	-321.0%	0.0%	0.0%	0.0%	-3.9%	-7.4%	-50.3%	0.05×	-1.07×	-42.09×	1.31×	0.0%	1	-2.08	2	C+
IGCIGC Pharma, Inc.	$0.21	-3.64×	4.08×	21.08×	-3.96×	-225.3%	29.7%	-860.3%	-552.1%	-107.0%	-144.8%	-24.4%	0.15×	-0.11×	0×	0.4×	0.0%	1	-18.6	1	C-
MLSSMilestone Scientific Inc.	$0.30	-3.9×	7.97×	2.5×	-4.05×	-405.4%	70.5%	-63.5%	-63.8%	-203.4%	-148.6%	-13.1%	0.36×	0.02×	-222.53×	1.81×	0.0%	3	-19.32	1	C-
MODDModular Medical, Inc.	$1.70	-0.43×	0.93×	0×	-0.21×	36.8%	0.0%	0.0%	0.0%	-217.9%	-206.4%	-229.5%	0.03×	0.25×	0×	4.03×	0.0%	1	-14.77	3	B-
Peer median	—	-2.98×	0.93×	0×	-3.96×	-225.3%	0.0%	0.0%	0.0%	-107.0%	-144.8%	-50.3%	0.05×	0.02×	0×	1.81×	0.0%	1	-14.77	1	—